The Proteasome Activator PA200/PSME4: An Emerging New Player in Health and Disease.

ABSTRACT: Proteasomes comprise a family of proteasomal complexes essential for maintaining protein homeostasis. Accordingly, proteasomes represent promising therapeutic targets in multiple human diseases. Several proteasome inhibitors are approved for treating hematological cancers. However, their side effects impede their efficacy and broader therapeutic applications. Therefore, understanding the biology of the different proteasome complexes present in the cell is crucial for developing tailor-made inhibitors against specific proteasome complexes. Here, we will discuss the structure, biology, and function of the alternative Proteasome Activator 200 (PA200), also known as PSME4, and summarize the current evidence for its dysregulation in different human diseases. We hereby aim to stimulate research

SUBMITTER: Yazgili AS 

PROVIDER: S-EPMC9406137 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature